GlassScriptPhysician profile
Kristen L Schaefer
NPI 1417295809
$711.39
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $28.35 · 2023: $14.99 · 2024: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $683.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $95.46 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.76 | 2024 | Entyvio |
| Celgene Corporation | $74.21 | 2024 | Zeposia |
| Gilead Sciences, INC. | $66.51 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $66.43 | 2024 | Dupixent |
| Genzyme Corporation | $65.36 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.54 | 2024 | Trulance |
| Qol Medical, LLC | $31.02 | 2024 | Sucraid |
| Medtronic, INC. | $28.35 | 2022 | |
| Braintree Laboratories, INC. | $28.15 | 2023-2024 | Sutab, Suflave |
| Janssen Biotech, INC. | $25.83 | 2024 | Stelara |
| Ardelyx, INC. | $24.89 | 2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $23.54 | 2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $20.20 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $19.77 | 2024 | Bylvay |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $14.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.